(NASDAQ: DFTX) Definium Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.05%.
Definium Therapeutics's earnings in 2026 is -$353,785,000.On average, 19 Wall Street analysts forecast DFTX's earnings for 2026 to be -$402,549,946, with the lowest DFTX earnings forecast at -$451,661,066, and the highest DFTX earnings forecast at -$296,279,125. On average, 19 Wall Street analysts forecast DFTX's earnings for 2027 to be -$285,274,472, with the lowest DFTX earnings forecast at -$547,787,182, and the highest DFTX earnings forecast at -$167,891,504.
In 2028, DFTX is forecast to generate -$113,728,186 in earnings, with the lowest earnings forecast at -$271,259,999 and the highest earnings forecast at $459,938,070.